文献速递妇科肿瘤

晚期上皮性卵巢癌:更多选择是否意味着更大获益?

Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?
PubMed 文献 · J Clin Oncol · 2019-04-19

本文为肿瘤学大查房系列文章,以一例51岁女性晚期高级别浆液性卵巢癌病例为引,描述其诊断与治疗挑战,回顾相关文献,并总结作者建议的管理方法,以帮助读者将关键研究结果应用于临床实践。

要点

  • 病例为51岁女性,表现为腹痛腹胀,影像见11.6cm盆腔肿块、腹膜后淋巴结肿大、右肾积水及肠系膜肿瘤沉积。
  • 血清CA-125升高至1,149 U/mL,行初次肿瘤细胞减灭术,达R0切除,最终病理为ⅡIC期高级别浆液性癌。
  • 胚系基因检测未发现BRCA1、BRCA2、BRIP1、RAD51C或RAD51D基因突变,术后接受辅助化疗。

核心结论

  • 本文通过病例展示和文献回顾,总结作者建议的管理方法,以帮助读者将关键研究结果应用于临床实践。

研究设计与样本

  • 本文为肿瘤学大查房系列文章,以病例报告形式呈现,并回顾相关文献。

主要发现

  • 患者为51岁健康女性,因腹痛腹胀就诊,CT见11.6cm盆腔肿块、腹膜后淋巴结肿大、右肾积水及肠系膜肿瘤沉积。
  • 血清CA-125为1,149 U/mL,行初次肿瘤细胞减灭术,术中见双侧卵巢肿块、盆腔及腹主动脉旁淋巴结肿大、4cm大网膜肿瘤,子宫和直肠乙状结肠有粘连肿瘤沉积,所有肉眼肿瘤均切除。
  • 最终病理为卵巢来源高级别浆液性癌,因上腹部受累且肿瘤沉积大于2cm及腹膜后淋巴结受累定为ⅡIC期。
  • 胚系基因检测未发现BRCA1、BRCA2、BRIP1、RAD51C或RAD51D基因突变,患者在理想(R0)切除后接受辅助化疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A healthy 51-year-old woman presented with increasing abdominal and pelvic pain. Computed tomography imaging of the abdomen and pelvis showed an 11.6-cm pelvic mass, retroperitoneal lymphadenopathy, right hydronephrosis, and mesenteric tumor deposits ( Fig 1A ). A serum CA-125 was elevated at 1,149 U/mL. She underwent primary surgical cytoreduction including hysterectomy, bilateral salpingo-oophorectomy, appendectomy, resection of pelvic tumor, omentectomy, and low anterior resection with colorectal anastomosis. Intraoperatively, she was noted to have bilateral ovarian masses, pelvic and para-aortic lymphadenopathy, and a 4-cm omental tumor; in addition, both the uterus and rectosigmoid colon had adherent tumor deposits. All gross tumor was resected during the procedure. Final pathology confirmed high-grade serous carcinoma of ovarian origin ( Fig 1B ) that was determined to be stage IIIC as a result of upper abdominal involvement with greater than 2-cm tumor deposits, as well as retroperitoneal lymph node involvement. She underwent germline genetic testing, which did not identify a mutation in the BRCA1, BRCA2, BRIP1, RAD51C, or RAD51D genes. She presented for adjuvant chemotherapy after an optimal (R0) resection.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bouberhan S, Shea M, Cannistra SA, et al. Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits? J Clin Oncol. 2019. PMID: 31002579. doi:10.1200/JCO.19.00500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。